{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T16:59:14Z","timestamp":1790441954135,"version":"4.1.0"},"reference-count":88,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100012021","name":"Iran University of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012021","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Protein Expression and Purification"],"published-print":{"date-parts":[[2027,1]]},"DOI":"10.1016\/j.pep.2026.106998","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T14:27:28Z","timestamp":1787927248000},"page":"106998","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Nanobodies (Nbs) in virology and viral diseases: Applications in viral detection, neutralization, and therapy"],"prefix":"10.1016","volume":"243","author":[{"given":"Maryam","family":"Mohebbi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Hamidreza","family":"Monavari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naghmeh","family":"Hadidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahimeh","family":"Safarnezhad Tameshkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morteza","family":"Nouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1364-5743","authenticated-orcid":false,"given":"Mohammad Hadi","family":"Karbalaie Niya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pep.2026.106998_bib1","series-title":"Tracking Universal Health Coverage: 2023 Global Monitoring Report","year":"2023"},{"issue":"7181","key":"10.1016\/j.pep.2026.106998_bib2","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1038\/nature06536","article-title":"Global trends in emerging infectious diseases","volume":"451","author":"Jones","year":"2008","journal-title":"Nature"},{"issue":"7919","key":"10.1016\/j.pep.2026.106998_bib3","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/s41586-022-04788-w","article-title":"Climate change increases cross-species viral transmission risk","volume":"607","author":"Carlson","year":"2022","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.pep.2026.106998_bib4","doi-asserted-by":"crossref","first-page":"610","DOI":"10.3390\/biom15050610","article-title":"Small but mighty: nanobodies in the fight against infectious diseases","volume":"15","author":"Jiang","year":"2025","journal-title":"Biomolecules"},{"issue":"23","key":"10.1016\/j.pep.2026.106998_bib5","doi-asserted-by":"crossref","first-page":"5639","DOI":"10.3390\/cancers15235639","article-title":"Small antibodies with big applications: nanobody-based cancer diagnostics and therapeutics","volume":"15","author":"Zhang","year":"2023","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.pep.2026.106998_bib6","doi-asserted-by":"crossref","DOI":"10.1099\/jgv.0.001731","article-title":"Nanobodies in the limelight: multifunctional tools in the fight against viruses","volume":"103","author":"Moliner-Morro","year":"2022","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.pep.2026.106998_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1303353","article-title":"Nanobodies: a promising approach to treatment of viral diseases","volume":"14","author":"Minatel","year":"2024","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.pep.2026.106998_bib8","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s40259-019-00392-z","article-title":"The therapeutic potential of nanobodies","volume":"34","author":"Jov\u010devska","year":"2020","journal-title":"BioDrugs"},{"issue":"9","key":"10.1016\/j.pep.2026.106998_bib9","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1007\/s00216-019-01633-4","article-title":"Nanobody: outstanding features for diagnostic and therapeutic applications","volume":"411","author":"Salvador","year":"2019","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.pep.2026.106998_bib10","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.pharmthera.2016.06.012","article-title":"Nanobodies\u00ae as inhaled biotherapeutics for lung diseases","volume":"169","author":"Van Heeke","year":"2017","journal-title":"Pharmacol. Therapeut."},{"issue":"1","key":"10.1016\/j.pep.2026.106998_bib11","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1146\/annurev-biochem-063011-092449","article-title":"Nanobodies: natural single-domain antibodies","volume":"82","author":"Muyldermans","year":"2013","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.pep.2026.106998_bib12","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.3389\/fimmu.2017.01589","article-title":"Camelid single-domain antibodies: historical perspective and future outlook","volume":"8","author":"Arbabi-Ghahroudi","year":"2017","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.pep.2026.106998_bib13","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.drudis.2016.04.003","article-title":"Nanobodies as therapeutics: big opportunities for small antibodies","volume":"21","author":"Steeland","year":"2016","journal-title":"Drug Discov. Today"},{"issue":"5","key":"10.1016\/j.pep.2026.106998_bib14","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.cell.2020.04.031","article-title":"Structural basis for potent neutralization of betacoronaviruses by single-domain camelid antibodies","volume":"181","author":"Wrapp","year":"2020","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.pep.2026.106998_bib15","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/nprot.2014.039","article-title":"A general protocol for the generation of Nanobodies for structural biology","volume":"9","author":"Pardon","year":"2014","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.pep.2026.106998_bib16","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.16228","article-title":"NaLi-H1: a universal synthetic library of humanized nanobodies providing highly functional antibodies and intrabodies","volume":"5","author":"Moutel","year":"2016","journal-title":"eLife"},{"issue":"3","key":"10.1016\/j.pep.2026.106998_bib17","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41594-018-0028-6","article-title":"Yeast surface display platform for rapid discovery of conformationally selective nanobodies","volume":"25","author":"McMahon","year":"2018","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.pep.2026.106998_bib18","series-title":"MAbs","article-title":"Delivery of ALX-0171 by inhalation greatly reduces respiratory syncytial virus disease in newborn lambs","year":"2018"},{"issue":"6530","key":"10.1016\/j.pep.2026.106998_bib19","doi-asserted-by":"crossref","DOI":"10.1126\/science.abe6230","article-title":"Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape","volume":"371","author":"Koenig","year":"2021","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.pep.2026.106998_bib20","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/hep.26430","article-title":"An alpaca nanobody inhibits hepatitis C virus entry and cell-to-cell transmission","volume":"58","author":"Tarr","year":"2013","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.pep.2026.106998_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1013878","article-title":"A highly potent and broadly accessible bispecific nanobody for the treatment of ebola virus infections","volume":"22","author":"Bu","year":"2026","journal-title":"PLoS Pathog."},{"issue":"8084","key":"10.1016\/j.pep.2026.106998_bib22","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41586-025-09438-5","article-title":"A nanobody specific to prefusion glycoprotein B neutralizes HSV-1 and HSV-2","volume":"646","author":"Vollmer","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.pep.2026.106998_bib23","doi-asserted-by":"crossref","first-page":"771","DOI":"10.3389\/fimmu.2017.00771","article-title":"Nanobody technology: a versatile toolkit for microscopic imaging, protein-protein interaction analysis, and protein function exploration","volume":"8","author":"Beghein","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.pep.2026.106998_bib24","doi-asserted-by":"crossref","first-page":"130","DOI":"10.3389\/fpls.2018.00130","article-title":"Nanobody-directed specific degradation of proteins by the 26S-proteasome in plants","volume":"9","author":"Baudisch","year":"2018","journal-title":"Front. Plant Sci."},{"key":"10.1016\/j.pep.2026.106998_bib25","article-title":"Nanobody-targeted E3-ubiquitin ligase complex degrades nuclear proteins","volume":"5","author":"Shin","year":"2015","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/j.pep.2026.106998_bib26","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms13061352","article-title":"Research progress on the application of neutralizing nanobodies in the prevention and treatment of viral infections","volume":"13","author":"Duan","year":"2025","journal-title":"Microorganisms"},{"key":"10.1016\/j.pep.2026.106998_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2022.105265","article-title":"A broad-spectrum nanobody targeting the C-terminus of the hepatitis B surface antigen for chronic hepatitis B infection therapy","volume":"199","author":"Wang","year":"2022","journal-title":"Antivir. Res."},{"issue":"10","key":"10.1016\/j.pep.2026.106998_bib28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0109367","article-title":"Protective effect of different anti-rabies virus VHH constructs against rabies disease in mice","volume":"9","author":"Terryn","year":"2014","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.pep.2026.106998_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0004902","article-title":"Post-exposure treatment with anti-rabies VHH and vaccine significantly improves protection of mice from lethal rabies infection","volume":"10","author":"Terryn","year":"2016","journal-title":"PLoS Neglected Trop. Dis."},{"issue":"5","key":"10.1016\/j.pep.2026.106998_bib30","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.tibtech.2014.03.001","article-title":"Nanobody-based products as research and diagnostic tools","volume":"32","author":"De Meyer","year":"2014","journal-title":"Trends Biotechnol."},{"issue":"4","key":"10.1016\/j.pep.2026.106998_bib31","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1016\/j.jia.2023.09.033","article-title":"A nanobody-based blocking enzyme-linked immunosorbent assay for detecting antibodies against pseudorabies virus glycoprotein E","volume":"23","author":"L\u00fc","year":"2024","journal-title":"J. Integr. Agric."},{"issue":"10","key":"10.1016\/j.pep.2026.106998_bib32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0013168","article-title":"Engineered Nanobodies for early and accurate diagnosis of dengue virus infection","volume":"19","author":"Pavan","year":"2025","journal-title":"PLoS Neglected Trop. Dis."},{"issue":"5","key":"10.1016\/j.pep.2026.106998_bib33","doi-asserted-by":"crossref","first-page":"721","DOI":"10.4014\/jmb.1112.12001","article-title":"Neutralization of human papillomavirus by specific nanobodies against major capsid protein L1","volume":"22","author":"Minaeian","year":"2012","journal-title":"J. Microbiol. Biotechnol."},{"issue":"1","key":"10.1016\/j.pep.2026.106998_bib34","article-title":"Special issue: nanobody","volume":"9","author":"Chames","year":"2020","journal-title":"Antibodies (Basel)"},{"issue":"1","key":"10.1016\/j.pep.2026.106998_bib35","doi-asserted-by":"crossref","first-page":"4420","DOI":"10.1038\/s41467-020-18174-5","article-title":"An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction","volume":"11","author":"Hanke","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.pep.2026.106998_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.108192","article-title":"The role of lovastatin in the attenuation of COVID-19","volume":"101","author":"Karampoor","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.pep.2026.106998_bib37","series-title":"Angiotensin Converting Enzyme Inhibitors, a Risk Factor of Poor Outcome in Diabetic Patients with COVID-19 Infection","author":"Aghaaliakbari","year":"2020"},{"issue":"1","key":"10.1016\/j.pep.2026.106998_bib38","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/mco2.60","article-title":"A potent neutralizing nanobody against SARS\u2010CoV\u20102 with inhaled delivery potential","volume":"2","author":"Gai","year":"2021","journal-title":"MedComm"},{"issue":"10","key":"10.1016\/j.pep.2026.106998_bib39","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02438-20","article-title":"Potent neutralization of SARS-CoV-2 by hetero-bivalent alpaca nanobodies targeting the spike receptor-binding domain","volume":"95","author":"Ma","year":"2021","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.pep.2026.106998_bib40","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-74761-y","article-title":"Development of humanized tri-specific nanobodies with potent neutralization for SARS-CoV-2","volume":"10","author":"Dong","year":"2020","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/j.pep.2026.106998_bib41","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24065994","article-title":"NANOBODIES\u00ae: a review of diagnostic and therapeutic applications","volume":"24","author":"Jin","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"18","key":"10.1016\/j.pep.2026.106998_bib42","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00837-18","article-title":"A novel nanobody targeting Middle East respiratory syndrome coronavirus (MERS-CoV) receptor-binding domain has potent cross-neutralizing activity and protective efficacy against MERS-CoV","volume":"92","author":"Zhao","year":"2018","journal-title":"J. Virol."},{"issue":"8","key":"10.1016\/j.pep.2026.106998_bib43","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1012438","article-title":"Structure defining of ultrapotent neutralizing nanobodies against MERS-CoV with novel epitopes on receptor binding domain","volume":"20","author":"Ma","year":"2024","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.pep.2026.106998_bib44","series-title":"Detection of Oseltamivir Resistant Influenza A\/H3N2 Viruses by real-time RT-PCR","author":"Karbalaie-Niya","year":"2015"},{"issue":"1","key":"10.1016\/j.pep.2026.106998_bib45","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/s11262-024-02119-x","article-title":"Genetic characterization of influenza B virus and oseltamivir resistance in pediatric patients with acute respiratory infections: a cross-sectional study","volume":"61","author":"Alizadeh","year":"2025","journal-title":"Virus Genes"},{"key":"10.1016\/j.pep.2026.106998_bib46","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.963978","article-title":"Research progress and applications of nanobody in human infectious diseases","volume":"13","author":"Mei","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"5","key":"10.1016\/j.pep.2026.106998_bib47","first-page":"495","article-title":"Molecular epidemiology of human respiratory syncytial virus (HRSV) in Iranian military trainees with acute respiratory symptoms in 2017","volume":"12","author":"Niya","year":"2020","journal-title":"Iran. J. Microbiol."},{"issue":"9","key":"10.1016\/j.pep.2026.106998_bib48","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/s41573-022-00495-3","article-title":"Antibodies to combat viral infections: development strategies and progress","volume":"21","author":"Pantaleo","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"issue":"3","key":"10.1016\/j.pep.2026.106998_bib49","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2217\/fvl-2016-0096","article-title":"Current diagnostic methods for HIV","volume":"12","author":"Tavakoli","year":"2017","journal-title":"Future Virol."},{"key":"10.1016\/j.pep.2026.106998_bib50","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.3389\/fimmu.2017.01603","article-title":"Nanobodies and nanobody-based human heavy chain antibodies as antitumor therapeutics","volume":"8","author":"Bannas","year":"2017","journal-title":"Front. Immunol."},{"issue":"24","key":"10.1016\/j.pep.2026.106998_bib51","doi-asserted-by":"crossref","first-page":"12069","DOI":"10.1128\/JVI.01379-08","article-title":"Llama antibody fragments with cross-subtype human immunodeficiency virus type 1 (HIV-1)-neutralizing properties and high affinity for HIV-1 gp120","volume":"82","author":"Forsman","year":"2008","journal-title":"J. Virol."},{"issue":"6","key":"10.1016\/j.pep.2026.106998_bib52","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1084\/jem.20112655","article-title":"Potent and broad neutralization of HIV-1 by a llama antibody elicited by immunization","volume":"209","author":"McCoy","year":"2012","journal-title":"J. Exp. Med."},{"issue":"5","key":"10.1016\/j.pep.2026.106998_bib53","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1083\/jcb.201409074","article-title":"Nanobodies and recombinant binders in cell biology","volume":"209","author":"Helma","year":"2015","journal-title":"JCB (J. Cell Biol.)"},{"key":"10.1016\/j.pep.2026.106998_bib54","series-title":"Detection of Human Papilloma Virus (HPV) Infection in Colorectal Cancer and Viral Genome Integration Status","author":"Karbalaie","year":"2022"},{"key":"10.1016\/j.pep.2026.106998_bib55","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.molimm.2019.02.022","article-title":"Nanobody against the E7 oncoprotein of human papillomavirus 16","volume":"109","author":"Li","year":"2019","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.pep.2026.106998_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2021.108684","article-title":"A novel intracellular nanobody against HPV16 E6 oncoprotein","volume":"225","author":"Zhang","year":"2021","journal-title":"Clin. Immunol."},{"issue":"9","key":"10.1016\/j.pep.2026.106998_bib57","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20092088","article-title":"Single-domain antibodies represent novel alternatives to monoclonal antibodies as targeting agents against the human papillomavirus 16 E6 protein","volume":"20","author":"Togtema","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.pep.2026.106998_bib58","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s12887-025-06458-y","article-title":"Diagnosis of EBV and HCMV infections in pediatric heart transplant recipients","volume":"26","author":"Gabeleh","year":"2025","journal-title":"BMC Pediatr."},{"issue":"1","key":"10.1016\/j.pep.2026.106998_bib59","first-page":"1","article-title":"A survey of HBV Core\/pre-core mutations in Iraqi patients with chronic hepatitis","volume":"23","author":"Jawazeri","year":"2023","journal-title":"Hepat. Mon."},{"key":"10.1016\/j.pep.2026.106998_bib60","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.micpath.2017.01.060","article-title":"Prevalence of resistant associated variants (RAVs) in the na\u00efve HCV patient candidate for direct acting antiviral (DAA) therapy","volume":"105","author":"Niya","year":"2017","journal-title":"Microb. Pathog."},{"issue":"3","key":"10.1016\/j.pep.2026.106998_bib61","first-page":"216","article-title":"Polymorphism of IL-28B gene (rs12979860) in HCV genotype 1patients treated by pegylated interferon and ribavirin","volume":"11","author":"Tameshkel","year":"2016","journal-title":"Iranian J. Pathol."},{"issue":"10","key":"10.1016\/j.pep.2026.106998_bib62","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1007\/s00705-020-04728-x","article-title":"Resistance-associated substitutions (RASs) to HCV direct-acting antivirals (DAAs) at baseline of treatment in thalassemia patients: a referral center study: FS Tameshkel et al","volume":"165","author":"Safarnezhad Tameshkel","year":"2020","journal-title":"Arch. Virol."},{"key":"10.1016\/j.pep.2026.106998_bib63","article-title":"Identification of two novel neutralizing nanobodies against swine hepatitis E virus","volume":"13","author":"Chen","year":"2022","journal-title":"Front. Microbiol."},{"issue":"9","key":"10.1016\/j.pep.2026.106998_bib64","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26093982","article-title":"Highly potent neutralizing nanobodies acting against chikungunya virus infection via inhibiting multiple stages of the viral life cycle","volume":"26","author":"Song","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.pep.2026.106998_bib65","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003334","article-title":"Recombinant monovalent llama-derived antibody fragments (VHH) to rotavirus VP6 protect neonatal gnotobiotic piglets against human rotavirus-induced diarrhea","volume":"9","author":"Vega","year":"2013","journal-title":"PLoS Pathog."},{"issue":"13","key":"10.1016\/j.pep.2026.106998_bib66","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00660-20","article-title":"Nanobody-mediated neutralization reveals an achilles heel for norovirus","volume":"94","author":"Koromyslova","year":"2020","journal-title":"J. Virol."},{"issue":"6","key":"10.1016\/j.pep.2026.106998_bib67","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02005-18","article-title":"Structural basis of nanobodies targeting the prototype norovirus","volume":"93","author":"Ruoff","year":"2019","journal-title":"J. Virol."},{"issue":"2","key":"10.1016\/j.pep.2026.106998_bib68","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.antiviral.2010.05.012","article-title":"In vitro antiviral activity of single domain antibody fragments against poliovirus","volume":"87","author":"Thys","year":"2010","journal-title":"Antivir. Res."},{"issue":"7","key":"10.1016\/j.pep.2026.106998_bib69","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1128\/JVI.03017-15","article-title":"Five of five VHHs neutralizing poliovirus bind the receptor-binding site","volume":"90","author":"Strauss","year":"2016","journal-title":"J. Virol."},{"key":"10.1016\/j.pep.2026.106998_bib70","first-page":"9","article-title":"Dengue virus: the viral agent and its shedding, strategies for disease control and reducing its health impact","volume":"30","author":"Panahi","year":"2025","journal-title":"Ital. J. Gastroenterol. Hepatol."},{"issue":"6301","key":"10.1016\/j.pep.2026.106998_bib71","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1126\/science.aaf8505","article-title":"Specificity, cross-reactivity, and function of antibodies elicited by Zika virus infection","volume":"353","author":"Stettler","year":"2016","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.pep.2026.106998_bib72","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1021\/acsinfecdis.5c00205","article-title":"A high-affinity and potently neutralized nanobody against zika virus","volume":"11","author":"Hu","year":"2025","journal-title":"ACS Infect. Dis."},{"issue":"32","key":"10.1016\/j.pep.2026.106998_bib73","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aav5062","article-title":"Optimal therapeutic activity of monoclonal antibodies against chikungunya virus requires Fc-Fc\u03b3R interaction on monocytes","volume":"4","author":"Fox","year":"2019","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.pep.2026.106998_bib74","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.3389\/fimmu.2017.01234","article-title":"Unveiling a drift resistant cryptotope within marburgvirus nucleoprotein recognized by llama single-domain antibodies","volume":"8","author":"Garza","year":"2017","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.pep.2026.106998_bib75","doi-asserted-by":"crossref","first-page":"4403","DOI":"10.1128\/JVI.03402-13","article-title":"Mechanism of action and capsid-stabilizing properties of VHHs with an in vitro antipolioviral activity","volume":"88","author":"Schotte","year":"2014","journal-title":"J. Virol."},{"issue":"6","key":"10.1016\/j.pep.2026.106998_bib76","doi-asserted-by":"crossref","first-page":"374","DOI":"10.66224\/ibj.5197","article-title":"Genetically engineered probiotics: design, therapeutics, and clinical translation","volume":"29","author":"Boogari","year":"2025","journal-title":"Iran. Biomed. J."},{"issue":"8","key":"10.1016\/j.pep.2026.106998_bib77","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.1382","article-title":"Split\u2010Cas9\u2010based targeted gene editing and nanobody\u2010mediated proteolysis\u2010targeting chimeras optogenetically coordinated regulation of Survivin to control the fate of cancer cells","volume":"13","author":"Deng","year":"2023","journal-title":"Clin. Transl. Med."},{"issue":"4","key":"10.1016\/j.pep.2026.106998_bib78","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa1806311","article-title":"Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura","volume":"380","author":"Scully","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pep.2026.106998_bib79","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/978-1-61779-968-6_2","article-title":"Introduction to heavy chain antibodies and derived Nanobodies","author":"Vincke","year":"2012","journal-title":"Single Domain Antibod.: Method. Protocol."},{"issue":"8","key":"10.1016\/j.pep.2026.106998_bib80","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1158\/1535-7163.MCT-07-2384","article-title":"Improved tumor targeting of anti\u2013epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular Nanobody technology","volume":"7","author":"Tijink","year":"2008","journal-title":"Mol. Cancer Therapeut."},{"issue":"4","key":"10.1016\/j.pep.2026.106998_bib81","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1158\/1535-7163.MCT-11-0891","article-title":"Nanobodies targeting the hepatocyte growth factor: potential new drugs for molecular cancer therapy","volume":"11","author":"Vosjan","year":"2012","journal-title":"Mol. Cancer Therapeut."},{"issue":"10","key":"10.1016\/j.pep.2026.106998_bib82","doi-asserted-by":"crossref","first-page":"7346","DOI":"10.1074\/jbc.M007734200","article-title":"Camel single-domain antibodies as modular building units in bispecific and bivalent antibody constructs","volume":"276","author":"Conrath","year":"2001","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.pep.2026.106998_bib83","doi-asserted-by":"crossref","first-page":"5469","DOI":"10.1038\/s41467-021-25480-z","article-title":"A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19","volume":"12","author":"Huo","year":"2021","journal-title":"Nat. Commun."},{"issue":"6523","key":"10.1016\/j.pep.2026.106998_bib84","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1126\/science.abe4747","article-title":"Versatile and multivalent nanobodies efficiently neutralize SARS-CoV-2","volume":"370","author":"Xiang","year":"2020","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.pep.2026.106998_bib85","doi-asserted-by":"crossref","first-page":"5009","DOI":"10.3390\/ijms23095009","article-title":"Camelid single-domain antibodies: promises and challenges as lifesaving treatments","volume":"23","author":"Arbabi-Ghahroudi","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.pep.2026.106998_bib86","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/s41551-021-00699-9","article-title":"Optimization of therapeutic antibodies by predicting antigen specificity from antibody sequence via deep learning","volume":"5","author":"Mason","year":"2021","journal-title":"Nat. Biomed. Eng."},{"issue":"7873","key":"10.1016\/j.pep.2026.106998_bib87","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","article-title":"Highly accurate protein structure prediction with AlphaFold","volume":"596","author":"Jumper","year":"2021","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.pep.2026.106998_bib88","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines\u2014a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat. Rev. Drug Discov."}],"container-title":["Protein Expression and Purification"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104659282600121X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104659282600121X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T16:31:58Z","timestamp":1790440318000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S104659282600121X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,1]]},"references-count":88,"alternative-id":["S104659282600121X"],"URL":"https:\/\/doi.org\/10.1016\/j.pep.2026.106998","relation":{},"ISSN":["1046-5928"],"issn-type":[{"value":"1046-5928","type":"print"}],"subject":[],"published":{"date-parts":[[2027,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nanobodies (Nbs) in virology and viral diseases: Applications in viral detection, neutralization, and therapy","name":"articletitle","label":"Article Title"},{"value":"Protein Expression and Purification","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pep.2026.106998","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106998"}}